Revenue From Pah Research & Development Costs Subject To Reimbursement was Gossamer Bio’s largest product and service line in fiscal 2025, bringing in $16.00M of $48.47M (33%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Us License | $78.95M | — |
| Revenue From Pah Research & Development Costs Subject To Reimbursement | $10.25M | $16.00M |
| Row License | $11.72M | — |
| Revenue From Pah Research & Development Service Performance Obligation Satisfied During Reporting Period | $9.56M | $9.44M |
| Revenue From Ph-Ild Research & Development Costs Subject To Reimbursement | $2.38M | $13.58M |
| Revenue From Pah Commercial Costs Subject To Reimbursement | $538.00K | $5.55M |
| Revenue From Ph-Ild Research & Development Service Performance Obligation Satisfied During Reporting Period | $1.29M | $3.31M |
| Revenue From Ph-Ild Commercial Costs Subject To Reimbursement | $116.00K | $665.00K |
| Effect Of Exchange Rate Changes On Revenue | -$93.00K | -$72.00K |
| Total | $114.70M | $48.47M |
Gossamer Bio brought in $48.47M from its seven product and service lines in fiscal 2025, the year ended December 31, 2025. Gossamer Bio regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $114.70M. Revenue From Pah Research & Development Costs Subject To Reimbursement was the largest at $16.00M (33.0%), ahead of Revenue From Ph-Ild Research & Development Costs Subject To Reimbursement at $13.58M (28.0%) and Revenue From Pah Research & Development Service Performance Obligation Satisfied During Reporting Period at $9.44M (19.5%). The other three lines brought in $9.53M combined.
Compared with fiscal 2024, Revenue From Pah Commercial Costs Subject To Reimbursement grew fastest, up 932.3% to $5.55M, while Revenue From Pah Research & Development Service Performance Obligation Satisfied During Reporting Period fell the most, down 1.2% to $9.44M.
Gossamer Bio stopped reporting Us License ($78.95M in fiscal 2024) and Row License ($11.72M in fiscal 2024) as separate lines. The total is net of Effect Of Exchange Rate Changes On Revenue, which took $72.00K off revenue in fiscal 2025.
Gossamer Bio (GOSS) reports its revenue by product and service. In fiscal 2025, Revenue From Pah Research & Development Costs Subject To Reimbursement was its largest product and service line, bringing in $16.00M (33.0% of the total), followed by Revenue From Ph-Ild Research & Development Costs Subject To Reimbursement at $13.58M (28.0%).
Revenue From Pah Research & Development Costs Subject To Reimbursement was Gossamer Bio's largest product and service line in fiscal 2025, bringing in $16.00M, or 33.0% of the $48.47M total across its seven product and service lines.
Every figure comes from Gossamer Bio's annual financial filings, as reported. Each line keeps the name Gossamer Bio gives it, and years follow its fiscal calendar.
Gossamer Bio's revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.